Telehealth-based Symptom Management for Veterans Treated With Selinexor

Active, not recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Multiple MyelomaLarge-cell Lymphoma
Interventions
DRUG

Selinexor

Selinexor is an oral therapy that is FDA approved for multiple myeloma and diffuse large B-cell lymphoma that have returned after prior therapy. Side effects like nausea, vomiting, and fatigue can affect how long a patient is able to continue taking Selinexor, which could mean that treatment might stop sooner.

Trial Locations (1)

27705

Durham VA Medical Center, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Duke University

OTHER

lead

Durham VA Medical Center

FED